News Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Market Closed - OTC Markets Other stock markets 14:13:26 2024-06-26 EDT			5-day change	1st Jan Change
19.68 ^USD	+0.92%		-0.35%	-5.79%

06-25	Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China	DJ
06-25	Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novo Nordisk's Wegovy Weight-Loss Drug Gets Approval in China	06-25	DJ
Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions	06-24	CI
Innovent Reports Oncology Pipeline Updates at Investor Meeting	06-20	AQ
Innovent Biologics, Inc Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer	06-12	CI
Innovent Biologics, Inc. Presents at 2024 ASCO Annual Meeting on Clinical Data of Anti-CLDN18.2 ADC in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer	06-01	CI
Innovent Biologics, Inc. Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib (ROS1 Inhibitor) Publishes in JCO and Reports at 2024 ASCO Annual Meeting	06-01	CI
Innovent Biologics, Inc. Presents Phase 1 Clinical Data of First-In-Class PD-1/IL-2a Bispecific Antibody Fusion Protein in Melanoma, Colorectal Cancer and Other Solid Tumors at 2024 ASCO Annual Meeting	06-01	CI
Innovent Announces Picankibart Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA	05-29	AQ
Innovent Biologics, Inc. Announces Picankibart Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA	05-27	CI
Innovent Announces the New Drug Application of IBI311 has been accepted by the NMPA of China for Thyroid Eye Disease	05-22	AQ
Chinese Regulator Accepts Innovent Biologics' New Drug Application for Thyroid Eye Disease Drug	05-20	MT
Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311	05-20	CI
Innovent Biologics Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 and IBI343	05-20	AQ
Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints	05-10	AQ
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	05-06	CI
Innovent Biologics, Inc. Announces Board and Committee Changes	05-03	CI
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer	05-01	AQ
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	04-30	CI
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer	04-30	CI
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	04-17	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Innovent Biologics, Inc. OTC Markets

Equities

IVBIY

US45783L1017

Summary

Filters